Quantum BioPharma Ltd. (NASDAQ: QNTM) has taken a significant step toward advancing its investigational multiple sclerosis drug, Lucid-MS, by signing a Study Start-Up Agreement with Thermo Fisher Scientific’s clinical research business. The agreement, announced after the U.S. Food and Drug Administration cleared the company’s Investigational New Drug application in August 2026, will support the Phase 2 clinical trial of Lucid-MS for progressive MS. The move matters because it transitions the program from preclinical and early-stage testing into clinical implementation with a contract research organization experienced in central nervous system and MS studies.
Unlike many existing MS treatments that primarily target the immune system, Lucid-MS is designed to protect myelin, the protective coating around nerve fibers, by inhibiting PAD2, an enzyme implicated in myelin damage. This mechanism could offer a complementary or alternative strategy for progressive forms of the disease, which have limited treatment options. The randomized, double-blind, placebo-controlled trial will evaluate the candidate’s safety, tolerability and efficacy using clinical and radiological measures.
The implications of the agreement extend beyond trial logistics. By engaging Thermo Fisher’s clinical research business, Quantum BioPharma gains access to established infrastructure and expertise for executing a complex CNS trial, potentially reducing startup timelines and operational risk. For investors, the deal signals tangible progress toward a pivotal study, though the company has not yet announced enrollment dates or trial sites. Preclinical research and Phase 1 testing have provided encouraging findings, but Lucid-MS remains investigational, and no assurance can be given regarding trial outcomes.
Quantum BioPharma is dedicated to building a portfolio of innovative assets and biotech solutions for neurodegenerative and metabolic disorders, as well as alcohol misuse disorders. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., the company focuses on the research and development of Lucid-MS, a patented new chemical entity shown to prevent and reverse myelin degradation in preclinical models. For more information, visit www.QuantumBioPharma.com. The latest news and updates relating to QNTM are available in the company’s newsroom at https://ibn.fm/QNTM.
The announcement was disseminated through InvestorWire, a specialized communications platform focused on wire-grade press release syndication. InvestorWire is part of the Dynamic Brand Portfolio at IBN, which provides services including editorial syndication to 5,000+ outlets, press release enhancement, social media distribution and tailored corporate communications solutions. Full terms of use and disclaimers are available at https://www.InvestorWire.com/Disclaimer.
